AstraZeneca axes license agreement with Aridis, placing Europe-funded PhIII on hold
AstraZeneca is scrapping its license agreement with Aridis Pharmaceuticals on March 30, the British Big Pharma told the biotech last week, sending a European-funded Phase III into storage.
With the license terminated for AR-320, also known as suvratoxumab, Aridis can no longer continue a late-stage clinical trial testing the monoclonal antibody as a preemptive treatment for mechanically ventilated patients in intensive care who are colonized with S. aureus. The SAATELLITE-2 trial kicked off in September and was expected to enroll 564 patients who don’t have ventilator-associated pneumonia, or VAP.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters